CATEGORY

Peptide APIs

Peptides are short chains of amino acids linked by peptide bonds. Peptide APIs contribute to less than 1% of the API market. However, it is the segment with highest growth rate among Active pharmaceutical ingredients

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Peptide APIs.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Peptide APIs Suppliers


    Peptide APIs Supplier

    Find the right-fit peptide apis supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    Catalent Inc.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    1
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    33

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    30
    Social
    26
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    34
    Human rights
    32
    Community Environment
    15
    Corporate governance
    56
    Human resources
    26
    Security Scorecard
    79

    Threat indicators
    A
    91
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    F
    52
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    D
    62
    Application Security
    Detecting common website application vulnerbilities
    A
    100
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    A
    100
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    90
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    catalent.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    0
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    0
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    0
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    0
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    21
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Peptide APIs market report transcript


    Global Market Outlook on Peptide APIs

    The advances in chemical synthesis and peptide formulation boost the advent of new peptide APIs in the market.

    • The global annual demand of peptide API was ~1,600 kg 2016 and is growing at a CAGR of 10%
    • Increasing demand of peptide-based drugs and the patent expiration of blockbuster drugs are to boost peptide API market
    • Due to the complex and capital-intensive manufacturing, pharmaceutical companies seek CMOs as a best option for peptide API production to cut internal cost
    • Peptide API CMOs are concentrated in Europe and the US, followed by China and India

    Supply–Demand – Peptide API 

    CMOs are able to meet an increasing demand of innovator pharmaceutical companies, and they are increasing their capacity with a focus on producing API in the cost-efficient manner

    Supply

    • Currently, CMOs are able to meet the demand of pharmaceutical companies
    • However, the number of approved peptides would increase. It is important for CMO to be flexible enough to increase manufacturing capacity
    • The current focus of suppliers is to synthesize peptide API in low cost
    • Now, large peptides can be manufactured at both small and large-scale in cost-effective manner. Example: Trimeris and Roche were able to successfully commercialize enfuvirtide

    Demand

    • Most of the pharmaceutical companies buying peptides are located in the US, Europe, and Japan
    • Currently, demand in the emerging markets is less, as the generic products are still under review, and there is not much growth in the NCE segment
    • In the US, innovative US biotech companies are driving peptide API demand
    • Constant stream of NCEs in peptide gives potential opportunities to CMOs for expanding capacity

    End-Use Analysis – Peptide Drugs

    As the capability of CMOs enhance and more dosage forms available in the market, more suppliers would add peptide products

    • Oncology, diabetes, and obesity are the three prominent therapeutic areas, where peptide APIs are used
    • In addition, peptides are in high demand for treating cardiovascular, renal failure, etc., as antibiotics and vaccines
    • Currently, >80% of approved peptide drugs are administered by injection. The trend is moving toward oral and other delivery ways
    • About 9% of the peptide can now be taken orally and suppliers are collaborating with pharma majors to increase this share
    • Nasal is another way of delivering peptide drugs. Other ways, such as sublingual and transdermal dosage forms, are still under R&D

    Market Trends – Peptide API

    Acquisition of Medium/Small CMOs by Large CMOs and Capacity Expansion

    • Consolidation is expected to occur in peptide API market to support the growing industry demand and increasing number of clinical peptides in the pipeline
    • Bachem, Corden, and Polypeptide are the key players, who have done major investments. Large CMO players are upgrading their capabilities by investment in equipment, R&D, strategically positioning their facility (nearby raw material supply market) and innovative manufacturing methods

    Demand for Conjugated Peptides

    • Demand for conjugated peptides (lipidations, PEG-ylations, glycosylation) is on the rise, increasing the bioavailability of drugs. Hence, pharmaceutical companies are looking for CMOs, who have the capability to handle this
    • Trend as targeted synthesis of specifically glycosylated proteins and peptides demand CMO who can handle it. Bachem developed an industrial-scale process for Interferon beta-1a with Japanese partner GlyTech Inc.

    Emerging New Suppliers

    • Though the current market is oligopolistic in nature, however, new suppliers are emerging in Asia, such as Aurobindo Pharma (2012), etc.
    • The US, Europe, and Japan are the major regions, which drive peptide API. In another five years, Asia will be the growing market in peptide API space

    Innovative Technology for Peptide API Manufacturing

    • Peptide CMOs have been developing new technologies to increase yield, reduce manufacturing cost, and to enhance drug delivery
    • Current CMOs are mostly using SPSS, LPSS, and mixed phase synthesis to manufacture peptides. These chemical synthesis is now competing with recombinant DNA technology
    • New technology, namely Molecular Hiving developed by Sosei, which reduces the API manufacturing costs to one-tenth of the cost of existing methods (SPSS and LPSS). Other recent methods include fermentation and recombinant methods, but have few limitations.